Arcutis Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Arcutis Biotherapeutics
ARQT Stock  USD 10.77  0.63  6.21%   
Arcutis Biotherapeutics financial statements provide useful quarterly and yearly information to potential Arcutis Biotherapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Arcutis Biotherapeutics financial statements helps investors assess Arcutis Biotherapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Arcutis Biotherapeutics' valuation are summarized below:
Gross Profit
2.9 M
Profit Margin
(1.41)
Market Capitalization
1.3 B
Enterprise Value Revenue
7.674
Revenue
138.7 M
There are currently one hundred twenty fundamental signals for Arcutis Biotherapeutics that can be evaluated and compared over time across rivals. All traders should validate Arcutis Biotherapeutics' prevailing fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 244.6 M in 2024. Enterprise Value is likely to drop to about 373 M in 2024

Arcutis Biotherapeutics Total Revenue

62.59 Million

Check Arcutis Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcutis Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 31.2 M, Selling General Administrative of 182.2 M or Total Revenue of 62.6 M, as well as many indicators such as Price To Sales Ratio of 3.57, Dividend Yield of 0.0 or PTB Ratio of 2.65. Arcutis financial statements analysis is a perfect complement when working with Arcutis Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Arcutis Biotherapeutics Correlation against competitors.
For more information on how to buy Arcutis Stock please use our How to Invest in Arcutis Biotherapeutics guide.

Arcutis Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets260.7 M341.4 M129.8 M
Slightly volatile
Other Current Liabilities16.7 M33.2 M8.3 M
Slightly volatile
Total Current Liabilities23.4 M46.7 M11.8 M
Slightly volatile
Accounts Payable6.1 M12 M3.3 M
Slightly volatile
Cash64.4 M88.4 M33.2 M
Slightly volatile
Long Term Debt130 M201.8 M55.1 M
Slightly volatile
Cash And Short Term Investments237.1 M271.9 M118 M
Slightly volatile
Common Stock Shares Outstanding44.6 M69.3 M30.3 M
Slightly volatile
Long Term Debt Total87.4 M83.2 M36 M
Slightly volatile
Liabilities And Stockholders Equity260.7 M341.4 M129.8 M
Slightly volatile
Non Current Liabilities Total115.9 M206 M60.7 M
Slightly volatile
Capital Surpluse852.8 M812.2 M236.8 M
Slightly volatile
Other Current Assets20.6 M19.6 M5.6 M
Slightly volatile
Total Liabilities139.3 M252.7 M72.5 M
Slightly volatile
Total Current Assets255.3 M330.4 M127.1 M
Slightly volatile
Net Working Capital231.9 M283.8 M115.3 M
Slightly volatile
Other Liabilities21.4 K22.5 K120 K
Slightly volatile
Non Current Liabilities Other927.5 K976.4 K948.1 K
Slightly volatile
Short and Long Term Debt Total108.1 M205.9 M40.1 M
Slightly volatile
Property Plant And Equipment Net4.3 M3.9 M1.9 M
Slightly volatile
Other Assets77.3 K89.7 K58.1 K
Slightly volatile
Net Receivables27.1 M25.8 M4.2 M
Slightly volatile
Capital Lease Obligations4.3 M4.1 M1.8 M
Slightly volatile
Property Plant And Equipment Gross4.7 M5.8 M2.1 M
Slightly volatile
Short Term Debt1.1 M1.5 M489.9 K
Slightly volatile
Property Plant Equipment5.6 M5.3 M1.6 M
Slightly volatile
Common Stock Total Equity5 K5.8 K4.3 K
Slightly volatile
Intangible Assets5.5 M6.4 M7 M
Slightly volatile

Arcutis Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative182.2 M173.5 M38.3 M
Slightly volatile
Other Operating Expenses159.7 M300.7 M80.3 M
Slightly volatile
Research Development96.1 M110.6 M48.8 M
Slightly volatile
Total Operating Expenses158.8 M295.7 M79.9 M
Slightly volatile
Depreciation And Amortization2 M1.9 M702.2 K
Slightly volatile
Cost Of Revenue5.2 M5 M943 K
Slightly volatile
Non Operating Income Net Other147.9 K155.7 K752.4 K
Slightly volatile

Arcutis Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock10.7 M11.2 M16.6 M
Pretty Stable
Net Borrowings76.9 M143.8 M42.7 M
Slightly volatile
Stock Based Compensation40.8 M38.8 M9.7 M
Slightly volatile
Begin Period Cash Flow51.2 M54.9 M25.2 M
Slightly volatile
Depreciation1.6 M1.5 M438.5 K
Slightly volatile
Capital Expenditures406.6 K428 K1.9 M
Slightly volatile
Total Cash From Financing Activities179.9 M101.3 M91.7 M
Slightly volatile
End Period Cash Flow65.2 M89.3 M33.6 M
Slightly volatile
Change To Netincome76.1 M72.4 M17 M
Slightly volatile
Issuance Of Capital Stock171.4 M98.9 M106.4 M
Slightly volatile
Cash And Cash Equivalents Changes19.1 M36.1 M10.3 M
Slightly volatile
Dividends Paid107.3 M141.2 M82.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.573.7556192
Slightly volatile
Days Sales Outstanding150158746
Slightly volatile
Stock Based Compensation To Revenue0.620.65127.7691
Slightly volatile
Capex To Depreciation0.270.28143.0287
Pretty Stable
EV To Sales5.445.7272227
Slightly volatile
Payables Turnover0.440.41590.1664
Slightly volatile
Sales General And Administrative To Revenue26.529.8232.4689
Slightly volatile
Research And Ddevelopement To Revenue1.761.855143.1358
Slightly volatile
Capex To Revenue0.00680.00725.4753
Slightly volatile
Cash Per Share3.583.92262.3716
Slightly volatile
Days Payables Outstanding8348782.8 K
Very volatile
Income Quality0.680.94250.7965
Slightly volatile
Intangibles To Total Assets0.01390.01890.016
Very volatile
Current Ratio13.947.08059.4153
Slightly volatile
Receivables Turnover2.432.30970.6937
Slightly volatile
Graham Number10.5210.43457.141
Slightly volatile
Capex Per Share0.00590.00620.0361
Slightly volatile
Revenue Per Share0.90.860.1754
Slightly volatile
Interest Debt Per Share3.523.3510.9287
Slightly volatile
Debt To Assets0.620.59330.2692
Slightly volatile
Operating Cycle1.1 K1.1 K4 K
Slightly volatile
Days Of Payables Outstanding8348782.8 K
Very volatile
Ebt Per Ebit1.141.07441.1258
Slightly volatile
Quick Ratio6.466.7998.8837
Slightly volatile
Net Income Per E B T0.811.0120.9885
Slightly volatile
Cash Ratio1.81.89425.1488
Pretty Stable
Cash Conversion Cycle177242203
Very volatile
Days Of Sales Outstanding150158746
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.821.00170.9993
Pretty Stable
Fixed Asset Turnover16.0515.28362.7831
Slightly volatile
Debt Ratio0.620.59330.2692
Slightly volatile
Price Sales Ratio3.573.7556192
Slightly volatile
Asset Turnover0.180.17460.0308
Slightly volatile
Gross Profit Margin0.690.91630.7965
Very volatile

Arcutis Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap244.6 M257.4 M712.9 M
Slightly volatile
Enterprise Value373 M392.6 M724.9 M
Slightly volatile

Arcutis Fundamental Market Drivers

Cash And Short Term Investments271.9 M

Arcutis Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Arcutis Biotherapeutics Financial Statements

Arcutis Biotherapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Arcutis Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcutis Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcutis Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue59.6 M62.6 M
Cost Of Revenue5 M5.2 M
Stock Based Compensation To Revenue 0.65  0.62 
Sales General And Administrative To Revenue 29.82  26.50 
Research And Ddevelopement To Revenue 1.86  1.76 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.86  0.90 
Ebit Per Revenue(4.04)(4.25)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Arcutis Stock Analysis

When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY